Who is sponsoring NCT01498484?

NCT01498484 is sponsored by Atara Biotherapeutics.

What drugs are being tested in NCT01498484?

Interventions in NCT01498484: EBV-specific T cells (EBV-CTLs).

What condition does NCT01498484 study?

NCT01498484 studies EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma.

Is NCT01498484 still recruiting?

NCT01498484 is currently completed. Last updated 26 September 2022.

Are results published for NCT01498484?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-09-26 · How we verify

NCT01498484

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Completed Phase 2 Results posted Last updated 26 September 2022

What this trial tests

Phase 2 trial testing EBV-specific T cells (EBV-CTLs) in EBV-induced Lymphomas in 87 participants. Completed in 1 July 2019.

Timeline

1 December 2011

Primary endpoint
1 July 2019

1 July 2019

Quick facts

Lead sponsor	Atara Biotherapeutics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	87
Start date	1 December 2011
Primary completion	1 July 2019
Estimated completion	1 July 2019
Sites	1 location across United States

Drugs / interventions tested

EBV-specific T cells (EBV-CTLs) — full drug profile →

Conditions studied

EBV-induced Lymphomas — all drugs for EBV-induced Lymphomas →
EBV-associated Malignancies — all drugs for EBV-associated Malignancies →
Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma — all drugs for Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma →

Sponsor

Atara Biotherapeutics — full company profile →

Who can join

Eligibility, any sex, with EBV-induced Lymphomas or EBV-associated Malignancies. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective Response Rate (ORR)
Time frame: From Day 1 through 65.3 months after Day 1 dose
The ORR is defined as percentage of participants with best overall response of complete remission/response (CR) or partial remission/response (PR) based on investigator's assessment. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR is complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of the affected tissues when i

Sponsor's own description

This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced lymphomas and EBV-associated malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
Prockop S, Doubrovina E, Suser S, Heller G, et al · · 2020 · cited 190× · PMID 31689242 · DOI 10.1172/jci121127
Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
Cao Y, Xie L, Shi F, Tang M, et al · · 2021 · cited 86× · PMID 33436584 · DOI 10.1038/s41392-020-00376-4
Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
Grant ML, Bollard CM. · · 2018 · cited 22× · PMID 29198753 · DOI 10.1016/j.blre.2017.11.004
Recent Advances in Adult Post-Transplant Lymphoproliferative Disorder.
Markouli M, Ullah F, Omar N, Apostolopoulou A, et al · · 2022 · cited 18× · PMID 36497432 · DOI 10.3390/cancers14235949
Therapeutic approaches to Epstein-Barr virus cancers.
Soldan SS, Messick TE, Lieberman PM. · · 2022 · cited 14× · PMID 36174496 · DOI 10.1016/j.coviro.2022.101260
Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling.
Xiao Q, Liu Y, Shu X, Li Y, et al · · 2025 · cited 9× · PMID 40349096 · DOI 10.1186/s40164-025-00655-2
HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy.
Wan X, Young KH, Bai O. · · 2023 · cited 8× · PMID 37483605 · DOI 10.3389/fimmu.2023.1216610
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.
Zappa E, Vitali A, Anders K, Molenaar JJ, et al · · 2023 · cited 7× · PMID 37832507 · DOI 10.1016/j.ejca.2023.113347

Verify or expand the search:

Other Atara Biotherapeutics trials

Trials by the same sponsor.

NCT06429800 — A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus · Phase 1 · withdrawn
NCT06256484 — A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-H · Phase 1 · terminated
NCT03769467 — Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma · Phase 1, PHASE2 · terminated
NCT03283826 — Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis · Phase 1, PHASE2 · terminated
NCT02822495 — Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01498484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atara Biotherapeutics
Last refreshed: 26 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01498484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing